Search

Displaying results 4551 - 4560 of 8010 in total
  1. Drug

    Faldaprevir

    go.drugbank.com/drugs/DB11808
    Investigational

    Faldaprevir has been investigated for the treatment of Chronic Hepatitis C.

    Categories: Antivirals for Systemic Use, Antiinfectives for Systemic Use
  2. Drug

    Atrazine

    go.drugbank.com/drugs/DB07392
    Experimental

    (From The Merck Index, 11th ed) … Inhalation hazard is low and there are no apparent skin manifestations or other toxicity in humans.

    Categories: Compounds used in a research, industrial, or household setting
  3. Drug

    Zunsemetinib

    go.drugbank.com/drugs/DB16502
    Investigational

    ATI-450 was under investigation in clinical trials (NCT05279417 and NCT05216224) for treating patients with rheumatoid arthritis and hidradenitis suppurativa, respectively. … Zunsemetinib is being investigated in a new clinical trial (NCT06374459) for the treatment of hormone receptor-positive and HER2-negative metastatic breast cancer with bone metastasis.

    Categories: Experimental Unapproved Treatments for COVID-19
  4. Drug

    D2C7 immunotoxin

    go.drugbank.com/drugs/DB17540
    Investigational

    D2C7 immunotoxin (D2C7-IT) is an investigational dual-specific monoclonal antibody targeting EGFRwt and EGFRvIII with a genetically engineered form of the _Pseudomonas exotoxin_, PE38-KDEL. … D2C7-IT is under investigation in clinical trial NCT04160494 (D2C7-IT With Atezolizumab for Recurrent Gliomas).

  5. Drug

    Diaminopropanol tetraacetic acid

    go.drugbank.com/drugs/DB12362
    ApprovedWithdrawn

    Diaminohydroxypropanetetraacetic acid has been investigated for the treatment of Vascular Disease, Coronary Disease, Myocardial Ischemia, Coronary Restenosis, and Coronary Artery Disease, among others.

  6. Drug

    Chlormezanone

    go.drugbank.com/drugs/DB01178
    ApprovedWithdrawn

    It has been suggested for use in the treatment of muscle spasm.

  7. Drug

    Remibrutinib

    go.drugbank.com/drugs/DB16852
    ApprovedInvestigational

    The FDA approved remibrutinib on September 30, 2025 as the only oral, targeted treatment for chronic spontaneous urticaria.

  8. Drug

    HNM01

    go.drugbank.com/drugs/DB06531
    Experimental

    It entered Phase 1 clinical trials for the treatment of HIV infections but was discontinued during this phase … The drug hNM01, a humanized monoclonal antibody developed by SRD Pharmaceuticals, Inc., targets the V(3) region of the HIV-1 envelope protein gp120, functioning as an HIV replication inhibitor.

  9. Drug

    Motavizumab

    go.drugbank.com/drugs/DB06310
    Investigational

    Categories: Antiinfectives for Systemic Use
  10. Drug

    Haemagglutinin-strain B

    go.drugbank.com/drugs/DB15482
    ApprovedInvestigational

    Mixtures: Influvac Suspension for Injection